Our regenerative innovations are designed to harness the body’s own ability to heal.

Humacyte’s platform technology has the potential to change the lives of countless people around the world by overcoming the current limitations in existing standards of care. We are leveraging our scalable technology platform to develop bioengineered human tissues for use in the treatment of diseases and conditions across a wide range of clinical needs. We are initially using our technology to bioengineer and manufacture the Human Acellular Vessel™, or HAV™, to address the significant unmet needs across multiple potential indications in vascular repair, reconstruction and replacement. The HAV is currently being investigated across multiple clinical trials in vascular trauma, AV access for hemodialysis, and peripheral arterial disease. Our pipeline vision is to evolve the utility of the HAV technology and develop future opportunities for coronary artery bypass grafting, pediatric heart surgery, the delivery of cellular therapies- including transplant of islet cells to treat Type 1 diabetes patients.

Humacyte has successfully developed the Human Acellular Vessel (HAV) from concept to wholly owned commercial-scale production in our manufacturing facilities, which have the capacity to provide thousands of vessels for treating patients in need. The HAV is created through a precise process involving the three major steps.

The HAV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Our Pipeline


1 of 6

Vascular Trauma

2 of 6

Dialysis AV Access

3 of 6

Peripheral Arterial Disease (PAD)

4 of 6

Coronary Artery Bypass Grafting (CABG)

5 of 6


6 of 6
Scroll to Top